Platinum-resistant recurrent ovarian cancer without germline BRCA1/2 mutation, 90% high-grade serous≥3 prior linesSomatic BRCA mutation status and mutation of HRR-related genes assessed. This evidence concerns the gene BRCA1 and ovarian carcinoma.